Baseline characteristics
| . | All patients . | ASCT immediately after PD-1 treatment . | Received intervening therapy between PD-1 and ASCT . |
|---|---|---|---|
| N (%) | 78 (100) | 58 (74) | 20 (26) |
| Male, n (%) | 52 (67) | 40 (69) | 12 (60) |
| Age at ASCT, median (range), y | 35 (19-73) | 33 (21-65) | 40 (19-73) |
| HL subtype, n (%) | |||
| Nodular sclerosing | 61 (78) | 47 (81) | 14 (70) |
| Classic HL NOS | 10 (13) | 5 (9) | 5 (25) |
| Mixed cellularity | 6 (8) | 6 (10) | 0 (0) |
| Lymphocyte-rich | 1 (1) | 0 (0) | 1 (5) |
| Stage at diagnosis, n (%) | |||
| II | 26 (33) | 22 (38) | 4 (20) |
| III | 24 (31) | 17 (29) | 7 (35) |
| IV | 28 (36) | 19 (33) | 9 (45) |
| Primary refractory, n (%) | 48 (62) | 39 (67) | 9 (45) |
| DOR to first-line treatment <12 mo, n (%) | 62 (79) | 49 (84) | 13 (65) |
| Extranodal disease at relapse, n (%) | 33/76 (57) | 20/57 (35) | 11/19 (58) |
| B symptoms at relapse, n (%) | 21/74 (28) | 13/56 (23) | 8/18 (44) |
| Received BV prior to ASCT, n (%) | 69 (88) | 50 (86) | 19 (95) |
| Refractory to BV, n (%) | 45 (58) | 31 (53) | 14 (70) |
| Refractory to line of therapy before anti-PD-1 mAb, n (%) | 55 (71) | 42 (72) | 13 (65) |
| Anti-PD-1 mAb, n (%) | |||
| Nivolumab | 51 (65) | 38 (66) | 13 (65) |
| Pembrolizumab | 26 (33) | 19 (33) | 7 (35) |
| Avelumab | 1 (1) | 1 (2) | 0 (0) |
| PD-1 therapy, n (%) | |||
| Monotherapy | 59 (76) | 43 (72) | 17 (85) |
| Combination therapy | 18 (23) | 16 (28) | 2 (10) |
| Both monotherapy and combination therapy | 1 (1) | 0 (0) | 1 (5) |
| Number of cycles of anti-PD-1 treatment, median (range) | 6.5 (2-32) | 6 (3-28) | 8 (2-32) |
| Best response to anti-PD-1-based treatment, n (%) | |||
| CR | 33 (42) | 31 (53) | 2 (10) |
| PR | 30 (38) | 19 (33) | 11 (55) |
| SD | 9 (12) | 6 (10) | 3 (15) |
| PD | 6 (8) | 2 (3) | 4 (20) |
| Days from last dose of anti-PD-1 mAb to ASCT, median (range) | 52 (12-934) | 42 (12-194) | 139 (42-934) |
| Received intervening salvage therapy between PD-1 and ASCT, n (%) | 20 (26) | 0 (0) | 20 (100) |
| Pre-ASCT PET response status, n (%) | |||
| CR | 47 (59) | 33 (57) | 14 (65) |
| PR | 24 (31) | 19 (33) | 5 (25) |
| SD | 4 (5) | 3 (5) | 1 (5) |
| PD | 3 (4) | 3 (5) | 0 (0) |
| Systemic lines of therapy before ASCT, median (range) | 4 (3-7) | 4 (3-7) | 5 (4-7) |
| Number of systemic lines of therapy before ASCT, n (%) | |||
| 3 | 24 (31) | 24 (41) | 0 (0) |
| 4 | 28 (36) | 25 (43) | 3 (15) |
| ≥5 | 26 (33) | 9 (16) | 17 (85) |
| Number of modified AETHERA risk factors, n (%) | |||
| 1 | 4 (5) | 3 (5) | 1 (5) |
| 2 | 23 (29) | 17 (29) | 6 (30) |
| 3 | 30 (38) | 24 (41) | 6 (30) |
| ≥4 | 21 (27) | 14 (24) | 7 (35) |
| Conditioning regimen, n (%) | |||
| BEAM (BCNU, etoposide, cytarabine, melphalan) | 53 (68) | 42 (72) | 11 (55) |
| GemBuMel (gemcitabine, busulfan, melphalan) | 12 (15) | 6 (10) | 6 (30) |
| CBV (cyclophosphamide, BCNU, etoposide) | 7 (9) | 5 (9) | 2 (10) |
| CBV+Gem/Nav (cyclophosphamide, BCNU, etoposide, gemcitabine, navelbine) | 4 (5) | 3 (5) | 1 (5) |
| BEAC (BCNU, etoposide, cytarabine, cyclophosphamide) | 1 (1) | 1 (2) | 0 (0) |
| CBV + Mel (cyclophosphamide, BCNU, etoposide, melphalan) | 1 (1) | 1 (2) | 0 (0) |
| . | All patients . | ASCT immediately after PD-1 treatment . | Received intervening therapy between PD-1 and ASCT . |
|---|---|---|---|
| N (%) | 78 (100) | 58 (74) | 20 (26) |
| Male, n (%) | 52 (67) | 40 (69) | 12 (60) |
| Age at ASCT, median (range), y | 35 (19-73) | 33 (21-65) | 40 (19-73) |
| HL subtype, n (%) | |||
| Nodular sclerosing | 61 (78) | 47 (81) | 14 (70) |
| Classic HL NOS | 10 (13) | 5 (9) | 5 (25) |
| Mixed cellularity | 6 (8) | 6 (10) | 0 (0) |
| Lymphocyte-rich | 1 (1) | 0 (0) | 1 (5) |
| Stage at diagnosis, n (%) | |||
| II | 26 (33) | 22 (38) | 4 (20) |
| III | 24 (31) | 17 (29) | 7 (35) |
| IV | 28 (36) | 19 (33) | 9 (45) |
| Primary refractory, n (%) | 48 (62) | 39 (67) | 9 (45) |
| DOR to first-line treatment <12 mo, n (%) | 62 (79) | 49 (84) | 13 (65) |
| Extranodal disease at relapse, n (%) | 33/76 (57) | 20/57 (35) | 11/19 (58) |
| B symptoms at relapse, n (%) | 21/74 (28) | 13/56 (23) | 8/18 (44) |
| Received BV prior to ASCT, n (%) | 69 (88) | 50 (86) | 19 (95) |
| Refractory to BV, n (%) | 45 (58) | 31 (53) | 14 (70) |
| Refractory to line of therapy before anti-PD-1 mAb, n (%) | 55 (71) | 42 (72) | 13 (65) |
| Anti-PD-1 mAb, n (%) | |||
| Nivolumab | 51 (65) | 38 (66) | 13 (65) |
| Pembrolizumab | 26 (33) | 19 (33) | 7 (35) |
| Avelumab | 1 (1) | 1 (2) | 0 (0) |
| PD-1 therapy, n (%) | |||
| Monotherapy | 59 (76) | 43 (72) | 17 (85) |
| Combination therapy | 18 (23) | 16 (28) | 2 (10) |
| Both monotherapy and combination therapy | 1 (1) | 0 (0) | 1 (5) |
| Number of cycles of anti-PD-1 treatment, median (range) | 6.5 (2-32) | 6 (3-28) | 8 (2-32) |
| Best response to anti-PD-1-based treatment, n (%) | |||
| CR | 33 (42) | 31 (53) | 2 (10) |
| PR | 30 (38) | 19 (33) | 11 (55) |
| SD | 9 (12) | 6 (10) | 3 (15) |
| PD | 6 (8) | 2 (3) | 4 (20) |
| Days from last dose of anti-PD-1 mAb to ASCT, median (range) | 52 (12-934) | 42 (12-194) | 139 (42-934) |
| Received intervening salvage therapy between PD-1 and ASCT, n (%) | 20 (26) | 0 (0) | 20 (100) |
| Pre-ASCT PET response status, n (%) | |||
| CR | 47 (59) | 33 (57) | 14 (65) |
| PR | 24 (31) | 19 (33) | 5 (25) |
| SD | 4 (5) | 3 (5) | 1 (5) |
| PD | 3 (4) | 3 (5) | 0 (0) |
| Systemic lines of therapy before ASCT, median (range) | 4 (3-7) | 4 (3-7) | 5 (4-7) |
| Number of systemic lines of therapy before ASCT, n (%) | |||
| 3 | 24 (31) | 24 (41) | 0 (0) |
| 4 | 28 (36) | 25 (43) | 3 (15) |
| ≥5 | 26 (33) | 9 (16) | 17 (85) |
| Number of modified AETHERA risk factors, n (%) | |||
| 1 | 4 (5) | 3 (5) | 1 (5) |
| 2 | 23 (29) | 17 (29) | 6 (30) |
| 3 | 30 (38) | 24 (41) | 6 (30) |
| ≥4 | 21 (27) | 14 (24) | 7 (35) |
| Conditioning regimen, n (%) | |||
| BEAM (BCNU, etoposide, cytarabine, melphalan) | 53 (68) | 42 (72) | 11 (55) |
| GemBuMel (gemcitabine, busulfan, melphalan) | 12 (15) | 6 (10) | 6 (30) |
| CBV (cyclophosphamide, BCNU, etoposide) | 7 (9) | 5 (9) | 2 (10) |
| CBV+Gem/Nav (cyclophosphamide, BCNU, etoposide, gemcitabine, navelbine) | 4 (5) | 3 (5) | 1 (5) |
| BEAC (BCNU, etoposide, cytarabine, cyclophosphamide) | 1 (1) | 1 (2) | 0 (0) |
| CBV + Mel (cyclophosphamide, BCNU, etoposide, melphalan) | 1 (1) | 1 (2) | 0 (0) |